Rx-360, a global nonprofit pharmaceutical supply chain consortium, announced on Tuesday that it has partnered with Leucine, an AI-powered pharmaceutical manufacturing and compliance platform.
Through this collaboration, Rx-360 consortium members will receive complimentary access to Leucine's FDA Tracker Premium, an advanced regulatory intelligence platform designed to help pharmaceutical manufacturers proactively monitor FDA activity, assess risk, and stay continuously inspection-ready.
FDA Tracker Premium delivers real-time intelligence across FDA inspections, Form 483s, and warning letters -- providing deep analytics on investigators, subsystems, and enforcement trends.
The platform helps quality and compliance leaders predict potential risks, benchmark performance against industry peers, and prepare more effectively for upcoming inspections, Rx-360 said.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval